Synopsis:
Obesity is a major comorbidity in psoriatic disease. It increases inflammation, worsens disease severity, reduces treatment response, and raises cardiovascular risks and mortality. This GRAPPA workshop aims to equip rheumatologists and healthcare providers with evidence-based, multidisciplinary education on the link between psoriasis and obesity, along with updates on new therapeutic options.
Workshop learning objectives:
By the end of the workshop, participants will be able to:
- Describe the epidemiology, pathology, and impact of obesity on psoriasis (PsO) and psoriatic arthritis (PsA).
- Explain the mechanistic links between adipose tissue, inflammation, and disease activity.
- Assess clinical evidence for different strategies to treat obesity related to psoriatic disease.
- Implement patient-centered approaches for weight management in clinical care.
| Agenda - Thursday 29 October | ||||
|---|---|---|---|---|
|
1045-1245 |
Part 1: Cardiovascular comorbidities in psoriatic arthritis (PsA)
Chairpersons: TBC and TBC Welcome and introduction Introduction and updates in GRAPPA Cardiovascular (CV) comorbidities and management CV comorbidity data from the APLAR-SpA Registry Q&A Part 2: BMI is not just a number Chairpersons: TBC and TBC Obesity as a chronic disease The impact of obesity on psoriatic diseases Q&A |
|||
|
1245-1330 |
LUNCH |
|||
|
1330-1500 |
Part 3: Treating PsA patients with obesity
Chairpersons: TBC and TBC Approach to obesity management, tips for GLP-1 therapies Immunomodulatory effects of incretin therapies in skin and joint inflammation Case discussion, focusing on obesity Q&A Workshop review and closing |
|||
